Châtillon, France, April 30, 2026DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF ...
On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...
DBV plans to announce new data for its Viaskin Peanut peanut allergy drug at a conference later this week. The company awaits FDA feedback for the design of another study of Viaskin Peanut. DBV is ...
Shares of DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, took a sharp turn for the worse today. Investors reacting to disappointing news about the development of Viaskin ...
DBV Technologies has posted phase 3 data suggesting safety and compliance are unlikely to scuttle its hopes of winning approval of peanut allergy treatment Viaskin Peanut. Shares in DBV rose on the ...
Zacks Investment Research on MSN
DBV Technologies (DBVT) upgraded to buy: What does it mean for the stock?
DBV Technologies S.A. (DBVT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...
Shares in DBV Technologies have shot up after it presented positive clinical trial results with an immunotherapy for peanut allergy that was rejected by the FDA several years ago. The Paris, ...
Wondering if DBV Technologies at €3.62 is still priced for opportunity or if most of the upside is already in the rear-view mirror. The stock has recently posted returns of 3.4% over 7 days, 6.3% over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results